United States

Progenics Pharmaceuticals Inc (PGNX.OQ)

PGNX.OQ on NASDAQ Stock Exchange Global Select Market

21 Oct 2016
Change (% chg)

$-0.16 (-2.81%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for PGNX.OQ


Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company's products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their... (more)


Beta: 2.73
Market Cap(Mil.): $387.72
Shares Outstanding(Mil.): 69.99
Dividend: --
Yield (%): --


  PGNX.OQ Industry Sector
P/E (TTM): -- 44.43 36.35
EPS (TTM): -0.51 -- --
ROI: -29.53 -0.69 13.88
ROE: -39.62 -2.39 14.79

BRIEF-Valeant and Progenics announce the U.S. commercial launch of FDA-approved Relistor tablets

* Valeant and Progenics announce the U.S. commercial launch of FDA approved Relistor tablets Source text for Eikon: Further company coverage:

Sep 06 2016

Progenics Pharmaceuticals whistleblower wins another $3 million

A former Progenics Pharmaceuticals Inc chemist who last year won a $1.66 million verdict from a biotechnology company accused of retaliating against him for whistleblower claims was awarded at least $3.3 million more on Tuesday.

Aug 30 2016

BRIEF-Progenics Pharmaceuticals Q2 loss per share $0.08

* Progenics Pharmaceuticals announces second quarter 2016 financial and business results

Aug 04 2016

BRIEF-Valeant and Progenics announce FDA approvals for relistor

* Valeant expects to commence sales of relistor tablets in U.S. in Q3 of 2016

Jul 19 2016

BRIEF-Progenics Pharmaceuticals signs commercial license agreement with Selexis SA

* Under agreement, progenics will have use of Selexis CHO-M cell line and sure technology platform

Jun 21 2016

BRIEF-Progenics Pharma Q1 loss per share $0.18

* Progenics pharmaceuticals announces first quarter 2016 financial and business results

May 05 2016

Earnings vs. Estimates